Primary indication
We are developing EGF for the treatment of optic neuritis a frequent early manifestation of multiple sclerosis (MS) caused by inflammation and demyelination of the optic nerve.
Unmet medical need: Current treatment is limited to corticosteroids, which offer temporary symptom relief but do not address the underlying pathology.
Our approach: CNS-targeted delivery of EGF via xB3 aims to reduce inflammation and promote remyelination.
Patient population: US annual incidence estimated at 6.4 per 100'000, UK prevalence about 114 cases for 100'000.
Patient population: US annual incidence estimated at 6.4 per 100'000, UK prevalence about 114 cases for 100'000.
Clinical relevance: Positive outcomes in optic neuritis associated with MS would support broader application in chronic progressive forms of MS.
